Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference Jun 4, 2026 04:01PM
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jun 2, 2026 04:01PM
Praxis pauses vormatrigine study after trial misses primary endpoint Jun 1, 2026 04:15PM
Praxis Precision Medicines Provides Vormatrigine Program Update Jun 1, 2026 04:15PM
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results May 7, 2026 08:00AM
View Older Stories

May 5, 2026 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2026 04:01PM Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference
Apr 14, 2026 07:30AM Praxis Precision Medicines receives FDA acceptance for essential tremor drug
Apr 14, 2026 07:30AM Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor
Apr 13, 2026 08:01AM Praxis to present ulixacaltamide essential tremor data at AAN 2026
Apr 13, 2026 08:00AM Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026
Apr 6, 2026 08:00AM Praxis Precision Medicines reports positive trial results for epilepsy drug
Apr 6, 2026 08:00AM Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Apr 2, 2026 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 30, 2026 04:01PM FDA accepts Praxis PRAX application for epilepsy drug relutrigine
Mar 30, 2026 04:01PM Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
Mar 4, 2026 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 19, 2026 07:30AM Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
Feb 9, 2026 04:01PM Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
Feb 4, 2026 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 13, 2026 04:30PM Praxis Precision Medicines hires epilepsy expert Dr. Orrin Devinsky as head of clinical strategy
Jan 13, 2026 04:30PM Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy
Jan 12, 2026 08:04AM Praxis plans two drug applications by mid-February, raises $1.5 billion
Jan 12, 2026 08:00AM Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress
Jan 9, 2026 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 8, 2026 04:45PM Praxis appoints two board directors and promotes two executives
Jan 8, 2026 04:45PM Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments
Dec 29, 2025 08:01AM FDA grants breakthrough therapy designation to Praxis drug for essential tremor
Dec 29, 2025 08:00AM Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor
Dec 11, 2025 08:02AM Praxis plans to file NDA for relutrigine in rare epilepsies by early 2026
Dec 11, 2025 08:00AM Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
Dec 9, 2025 04:01PM Praxis gets FDA agreement to simplify elsunersen trial design
Dec 9, 2025 04:01PM Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy
Dec 8, 2025 08:00AM Praxis AES Wrap-up: Best-in-Class Potential Across Rare Pediatric and Adult Epilepsies
Dec 4, 2025 04:12PM Praxis stops EMBOLD study early after relutrigine shows efficacy
Dec 4, 2025 04:10PM Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
Dec 4, 2025 04:01PM Praxis receives FDA alignment on ulixacaltamide NDA submission plans
Dec 4, 2025 04:01PM Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor
Dec 3, 2025 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 24, 2025 04:01PM Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting
Nov 20, 2025 04:01PM Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Nov 6, 2025 08:00AM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 5, 2025 04:01PM Praxis Precision Medicines to Participate in Upcoming Investor Conferences
Nov 5, 2025 08:00AM Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Nov 4, 2025 08:00AM Praxis plans early 2026 NDA filing for relutrigine after FDA alignment
Nov 4, 2025 08:00AM Praxis announces accelerated development path for relutrigine in SCN2A and SCN8A DEE patients following positive FDA feedback
Oct 16, 2025 07:01AM Praxis reports positive phase 3 results for essential tremor drug
Oct 16, 2025 07:00AM Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor
Oct 2, 2025 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 4, 2025 04:01PM Praxis Precision Medicines to Participate in September Investor Conferences
Sep 3, 2025 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 29, 2025 08:00AM Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Aug 25, 2025 04:01PM Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline
Aug 6, 2025 04:01PM Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 5, 2025 06:09PM Praxis Precision Medicines to Participate in Upcoming Fireside Chat
View Older Stories